{
    "clinical_study": {
        "@rank": "43618", 
        "acronym": "IMRAS", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: PfRAS-infected", 
                "arm_group_type": "Experimental", 
                "description": "5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.\nChallenge occurs 3 weeks after final immunization."
            }, 
            {
                "arm_group_label": "Cohort 1: Noninfected", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo immunization. 5 doses of approximately 200 infectious bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 infectious bites.\nChallenge occurs 3 weeks after final immunization."
            }, 
            {
                "arm_group_label": "Cohort 1: Nonimmunized", 
                "arm_group_type": "Other", 
                "description": "No protective intervention given.\nChallenge occurs directly after screening."
            }, 
            {
                "arm_group_label": "Cohort 2: PfRAS-infected", 
                "arm_group_type": "Experimental", 
                "description": "3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.\nChallenge occurs 3 weeks after final immunization."
            }, 
            {
                "arm_group_label": "Cohort 2: Noninfected", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo. 3 to 7 doses of approximately 200 infectious bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.\nChallenge occurs 3 weeks after final immunization."
            }, 
            {
                "arm_group_label": "Cohort 2: Nonimmunized", 
                "arm_group_type": "Other", 
                "description": "No protective intervention given.\nChallenge occurs directly after screening."
            }, 
            {
                "arm_group_label": "Hyperimmunity PfRAS-infected", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1 sub-cohort\n3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. The target dose is dependent on protection results in cohort 1. This arm will receive the first 3 immunizations of Cohort 2.\nChallenge occurs 3 weeks after final immunization."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the safety, tolerability, and biomarkers of protection in healthy\n      malaria-na\u00efve adults, who will receive bites from Anopheles stephensi mosquitoes either\n      infected with Plasmodium falciparum Sporozoites (PfRAS) (true-immunization) or noninfected\n      (mock-immunization)."
        }, 
        "brief_title": "Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1 open-labeled study. In addition to safety and tolerability of  Plasmodium\n      falciparum Sporozoites (PfRAS), this study is a comprehensive, systems biology-based effort\n      to identify and validate biomarkers of protection with PfRAS immunization, comparing\n      sterility protected to nonprotected study subjects. The goal of the trial design is to\n      achieve approximately 50% sterile protection in order to facilitate the identification of\n      biomarkers and correlates of protection.\n\n      Following true-immunization or mock-immunization, study subjects and nonimmunized\n      infectivity controls will receive a challenge via the bites of 5 An stephensi mosquitoes\n      carrying infectious P falciparum sporozoites within a controlled clinical environment\n      (controlled human malaria infection, CHMI) to determine the level of sterile protection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adults (male or non-pregnant, non-breastfeeding female) 18-50 years of age\n             (inclusive).\n\n          -  Available and willing to participate for duration of study.\n\n          -  Able and willing to provide written informed consent.\n\n          -  Able to complete an Assessment of Understanding with a score of at least 70% correct.\n\n          -  In good general health with no clinically significant health problems as established\n             by medical history, physical exam and laboratory screening.\n\n          -  Females of childbearing potential must have a negative pregnancy test at screening\n             and agree to not become pregnant or breastfeed for the duration of the study. She\n             must be willing to use a reliable form of contraception during the study. Reliable\n             forms of birth control include use of condoms, diaphragm or cervical cap, birth\n             control pills, IUD or sperm killing products.\n\n          -  Agree to refrain from blood donation (except as required in this study) for 3 years\n             following P falciparum challenge.\n\n          -  Agree not to travel to a malaria-endemic region during the study.\n\n          -  Good peripheral venous access.\n\n        Exclusion Criteria:\n\n          -  Positive Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen (HBsAg), or\n             Hepatitis C virus (HCV) serology.\n\n          -  Positive sickle cell screening test, including evidence of sickle trait.\n\n          -  Positive by CSP or AMA1 ELISpot assay or ELISA\n\n          -  Anemia (below normal reference laboratory value of hemoglobin) on screening.\n\n          -  Weight less than 110 pounds.\n\n          -  Any history of malaria infection or travel to a malaria endemic region within 6\n             months prior to first immunization.\n\n          -  History of long-term residence (> 5 years) in area known to have significant\n             transmission of P falciparum [cumulative lifetime exposure].\n\n          -  Use of systemic immunosuppressant pharmacotherapy (inhaled and topical steroids are\n             allowed) within 60 days of scheduled leukapheresis or immunization.\n\n          -  Current significant medical condition (cardiovascular, hepatic, renal, pulmonary, or\n             hematological) or evidence of any other serious underlying medical condition\n             identified by medical history, physical examination, or laboratory examination\n             (includes bleeding disorders).\n\n          -  Plan for surgery between enrollment and day 28 post-challenge.\n\n          -  Receipt of immunoglobulin and/or any blood products within 90 days of scheduled\n             leukapheresis or immunization.\n\n          -  Evidence of increased cardiovascular disease risk (defined as > 5%-10%, 5-year risk)\n             as determined by the method of Gaziano (2008). Risk factors include sex, age (years),\n             systolic blood pressure (mm Hg), smoking status, body mass index (BMI, kg/m2),\n             reported diabetes status, and blood pressure.\n\n          -  An abnormal electrocardiogram (ECG), defined as one showing pathologic Q waves and\n             significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm\n             excluding isolated premature atrial contractions; right or left bundle branch block;\n             or advanced (secondary or tertiary) A-V heart block.\n\n          -  History of a splenectomy.\n\n          -  History of any other illness or condition which, in the investigator's judgment, may\n             substantially increase the risk associated with the subject's participation in the\n             protocol or compromise the scientific objectives. This may include psychiatric\n             disorders (such as personality disorders, anxiety disorders, or schizophrenia) or\n             behavioral tendencies (including active alcohol or drug abuse) discovered during the\n             screening process that in the opinion of the investigator would make compliance with\n             the protocol difficult.\n\n          -  History of anaphylactic or other severe response to mosquito bites (history of local\n             hypersensitivity reactions is allowed).\n\n          -  History of retinal disease, visual field changes, psoriasis, porphyria, or known\n             allergy to the anti-malarial chloroquine phosphate, which will be used to treat\n             subjects developing malaria after CHMI.\n\n          -  Participation in any study involving any investigational vaccine or drug within 90\n             days prior to the screening visit, or plan to participate in another investigational\n             vaccine/drug research during or within 1 month following participation in this study.\n\n          -  Use or planned use of any drug with antimalarial activity that would coincide with\n             immunization or challenge.\n\n          -  Anticipated use of medications known to cause drug reactions with chloroquine or\n             atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and\n             kaolin.\n\n          -  Any other significant findings which, in the investigator's judgment, may\n             substantially increase."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994525", 
            "org_study_id": "S-12-22"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1: PfRAS-infected", 
                    "Cohort 2: PfRAS-infected", 
                    "Hyperimmunity PfRAS-infected"
                ], 
                "description": "Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes", 
                "intervention_name": "PfRAS", 
                "intervention_type": "Biological", 
                "other_name": [
                    "True-immunization", 
                    "PfRAS infected Anopheles stephensi mosquitoes"
                ]
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: Noninfected", 
                    "Cohort 2: Noninfected"
                ], 
                "description": "Administered by the bite of noninfected Anopheles stephensi mosquitoes", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Mock-immunization", 
                    "Noninfected Anopheles stephensi mosquites"
                ]
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: PfRAS-infected", 
                    "Cohort 1: Noninfected", 
                    "Cohort 1: Nonimmunized", 
                    "Cohort 2: PfRAS-infected", 
                    "Cohort 2: Noninfected", 
                    "Cohort 2: Nonimmunized", 
                    "Hyperimmunity PfRAS-infected"
                ], 
                "description": "5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.", 
                "intervention_name": "Challenge", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "Bradley.Hickey@med.navy.mil", 
                "last_name": "Bradley Hickey, MD", 
                "phone": "850-479-0751"
            }, 
            "contact_backup": {
                "email": "Judith.Epstein@med.navy.mil", 
                "last_name": "Judith Epstein, MD", 
                "phone": "301-295-8025"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20889"
                }, 
                "name": "Naval Medical Research Center Clinical Trials Center (CTC)"
            }, 
            "investigator": [
                {
                    "last_name": "Bradley Hickey, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Judith Epstein, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alexandra Singer, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cindy Tamminga, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "Phase 1 Trial With Challenge to Assess the Safety and Biomarkers of Protection in Malaria-na\u00efve Adults of Immunization Via Mosquito Bite With Radiation-Attenuated Plasmodium Falciparum Sporozoites (IMRAS)", 
        "overall_contact": {
            "email": "Bradley.Hickey@med.navy.mil", 
            "last_name": "Bradley Hickey, MD", 
            "phone": "850-479-0751"
        }, 
        "overall_contact_backup": {
            "email": "Judith.Epstein@med.navy.mil", 
            "last_name": "Judith Epstein, MD", 
            "phone": "301-252-9026"
        }, 
        "overall_official": {
            "affiliation": "Naval Medical Research Center", 
            "last_name": "Bradley Hickey, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Occurrence of solicited adverse events (AE) from administration of study immunization (PfRAS)", 
                "measure": "Solicited adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Occurrence of unsolicited adverse events (AEs) from administration of immunization (PfRAS)", 
                "measure": "Unsolicited adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Occurrence of laboratory AEs from administration of study immunization (PfRAS)", 
                "measure": "Laboratory adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Occurrence of serious adverse events (SAEs) from administration of immunization (PfRAS)", 
                "measure": "Serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Occurrence of signs and symptoms related to malaria infection starting 7 days post-Controlled Human Malaria Infection (CHMI) (these will not be recorded as adverse events because they are expected as a result of malaria infection)", 
                "measure": "Signs and symptoms related to malaria infection", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Development of parasitemia and time to parasitemia after malaria challenge", 
                "measure": "Parasitemia", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994525"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Compare Peripheral Blood Mononuclear Cell(s) (PBMC) read-outs between protected and nonprotected subjects and between immunized and mock-immunized subjects.", 
                "measure": "Identify and validate immunological PBMC biomarkers", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Compare serum read-outs between protected and nonprotected subjects and between immunized and mock-immunized subjects.", 
                "measure": "Identify and validate immunological serum biomarkers", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Compare whole blood read-outs between protected and nonprotected subjects and between immunized and mock-immunized subjects.", 
                "measure": "Identify and validate whole blood immunological biomarkers", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Seattle Biomedical Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bill and Melinda Gates Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}